Literature DB >> 19629677

Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier.

Birk Poller1, Jürgen Drewe, Stephan Krähenbühl, Jörg Huwyler, Heike Gutmann.   

Abstract

Brain capillary endothelial cells form the blood-brain barrier (BBB), a highly selective permeability membrane between the blood and the brain. Besides tight junctions that prevent small hydrophilic compounds from passive diffusion into the brain tissue, the endothelial cells express different families of drug efflux transport proteins that limit the amount of substances penetrating the brain. Two prominent efflux transporters are the breast cancer resistance protein and P-glycoprotein (P-gp). During inflammatory reactions, which can be associated with an altered BBB, pro-inflammatory cytokines are present in the systemic circulation. We, therefore, investigated the effect of the pro-inflammatory cytokines interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) on the expression and activity of BCRP and P-gp in the human hCMEC/D3 cell line. BCRP mRNA levels were significantly reduced by IL-1beta, IL-6 and TNF-alpha. The strongest BCRP suppression at the protein level was observed after IL-1beta treatment. IL-1beta, IL-6 and TNF-alpha also significantly reduced the BCRP activity as assessed by mitoxantrone uptake experiments. P-gp mRNA levels were slightly reduced by IL-6, but significantly increased after TNF-alpha treatment. TNF-alpha also increased protein expression of P-gp but the uptake of the P-gp substrate rhodamine 123 was not affected by any of the cytokines. This in vitro study indicates that expression levels and activity of BCRP, and P-gp at the BBB may be altered by acute inflammation, possibly affecting the penetration of their substrates into the brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19629677     DOI: 10.1007/s10571-009-9431-1

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  30 in total

1.  Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier.

Authors:  Carola Förster; Malgorzata Burek; Ignacio A Romero; Babette Weksler; Pierre-Olivier Couraud; Detlev Drenckhahn
Journal:  J Physiol       Date:  2008-02-07       Impact factor: 5.182

2.  Peripheral cytokines profile in Parkinson's disease.

Authors:  M Reale; C Iarlori; A Thomas; D Gambi; B Perfetti; M Di Nicola; M Onofrj
Journal:  Brain Behav Immun       Date:  2008-07-17       Impact factor: 7.217

Review 3.  The blood-brain barrier in neuroinflammatory diseases.

Authors:  H E de Vries; J Kuiper; A G de Boer; T J Van Berkel; D D Breimer
Journal:  Pharmacol Rev       Date:  1997-06       Impact factor: 25.468

4.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

5.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

Authors:  A H Schinkel; E Wagenaar; C A Mol; L van Deemter
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

6.  Breast cancer resistance protein and P-glycoprotein expression in patients with newly diagnosed and therapy-refractory ulcerative colitis compared with healthy controls.

Authors:  Heike Gutmann; Petr Hruz; Christian Zimmermann; Alexander Straumann; Luigi Terracciano; Felix Hammann; Frank Lehmann; Christoph Beglinger; Juergen Drewe
Journal:  Digestion       Date:  2008-12-03       Impact factor: 3.216

7.  Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.

Authors:  Jurjen S Lagas; Robert A B van Waterschoot; Vicky A C J van Tilburg; Michel J Hillebrand; Nienke Lankheet; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

8.  The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies.

Authors:  Birk Poller; Heike Gutmann; Stephan Krähenbühl; Babette Weksler; Ignacio Romero; Pierre-Olivier Couraud; Gerald Tuffin; Jürgen Drewe; Jörg Huwyler
Journal:  J Neurochem       Date:  2008-12       Impact factor: 5.372

9.  Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.

Authors:  Salvatore Cisternino; Claire Mercier; Fanchon Bourasset; Françoise Roux; Jean-Michel Scherrmann
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

10.  Influence of tumor necrosis factor-alpha on the expression and function of P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT.

Authors:  David Théron; Sylvie Barraud de Lagerie; Sylviane Tardivel; Hélène Pélerin; Philippe Demeuse; Claire Mercier; Aloïse Mabondzo; Robert Farinotti; Bernard Lacour; Françoise Roux; François Gimenez
Journal:  Biochem Pharmacol       Date:  2003-08-15       Impact factor: 5.858

View more
  62 in total

Review 1.  Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier.

Authors:  Michelle A Erickson; Kenji Dohi; William A Banks
Journal:  Neuroimmunomodulation       Date:  2012-01-11       Impact factor: 2.492

Review 2.  Cytokine signaling modulates blood-brain barrier function.

Authors:  Weihong Pan; Kirsten P Stone; Hung Hsuchou; Vamshi K Manda; Yan Zhang; Abba J Kastin
Journal:  Curr Pharm Des       Date:  2011-11       Impact factor: 3.116

Review 3.  In vitro models of the blood-brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use.

Authors:  Hans C Helms; N Joan Abbott; Malgorzata Burek; Romeo Cecchelli; Pierre-Olivier Couraud; Maria A Deli; Carola Förster; Hans J Galla; Ignacio A Romero; Eric V Shusta; Matthew J Stebbins; Elodie Vandenhaute; Babette Weksler; Birger Brodin
Journal:  J Cereb Blood Flow Metab       Date:  2016-02-11       Impact factor: 6.200

Review 4.  Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  Immortalized human brain endothelial cell line HCMEC/D3 as a model of the blood-brain barrier facilitates in vitro studies of central nervous system infection by Cryptococcus neoformans.

Authors:  Kiem Vu; Babette Weksler; Ignacio Romero; Pierre-Olivier Couraud; Angie Gelli
Journal:  Eukaryot Cell       Date:  2009-09-18

6.  Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.

Authors:  Mackenzie L Cottrell; Kristine B Patterson; Heather M A Prince; Amanda Jones; Nicole White; Ruili Wang; Angela D M Kashuba
Journal:  Antivir Ther       Date:  2015-06-03

7.  Regulation of P-glycoprotein by human immunodeficiency virus-1 in primary cultures of human fetal astrocytes.

Authors:  Tamima Ashraf; Patrick T Ronaldson; Yuri Persidsky; Reina Bendayan
Journal:  J Neurosci Res       Date:  2011-08-08       Impact factor: 4.164

Review 8.  3D in vitro modeling of the central nervous system.

Authors:  Amy M Hopkins; Elise DeSimone; Karolina Chwalek; David L Kaplan
Journal:  Prog Neurobiol       Date:  2014-11-22       Impact factor: 11.685

9.  Cilostazol strengthens barrier integrity in brain endothelial cells.

Authors:  Shoji Horai; Shinsuke Nakagawa; Kunihiko Tanaka; Yoichi Morofuji; Pierre-Oliver Couraud; Maria A Deli; Masaki Ozawa; Masami Niwa
Journal:  Cell Mol Neurobiol       Date:  2012-12-07       Impact factor: 5.046

Review 10.  Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Menino Osbert Cotta
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.